Federal Circuit denies Novartis’ bid to halt generics
29-09-2022
Roche asks court for halt of Novartis unit’s generic launch
04-04-2022
rafapress / Shutterstock.com
The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
In a patent revocation and infringement counterclaim action between Teva and Novartis, His Honour Judge Richard Hacon found, in a decision handed down on November 10 2022, lack of inventive step with respect to two Novartis formulation patents (EP 2,964,202 and EP 3,124,018)
He also ruled that Teva’s generic product ‘Teva DFX’ did not infringe the patents on either normal construction or on equivalents. The dispute involved a swallowable tablet version of Novartis’ ‘Exjade’ used to treat blood iron overload, previously only available as a dispersible tablet in Europe since 2006.
Novartis’s patents are obvious
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Novartis, Teva, iron overload treatment, inventive step, generic drug maker, prior art, infringement, patent revocation, Teva DFX, Exjade, EPO
